Thrombopoietin Human
HEK293 cells.
Megakaryocyte colony-stimulating factor, Myeloproliferative leukemia virus oncogene ligand, C-mpl ligand, ML, Megakaryocyte growth and development factor, MGDF, TPO, MKCSF, MPLLG, MGC163194, THPO
Greater than 90.0% as determined by SDS-PAGE.
Description
TPO Human Recombinant produced in HEK293 cells is a single, glycosylated polypeptide chain containing 343 amino acids (22-353 a.a) and having a molecular mass of 36.8kDa.
TPO is fused to a 6 amino acid His-tag at C-terminus & purified by proprietary chromatographic techniques.
Product Specs
Megakaryocyte colony-stimulating factor, Myeloproliferative leukemia virus oncogene ligand, C-mpl ligand, ML, Megakaryocyte growth and development factor, MGDF, TPO, MKCSF, MPLLG, MGC163194, THPO
HEK293 cells.
DGSHMSPAPP ACDLRVLSKL LRDSHVLHSR LSQCPEVHPL PTPVLLPAVD FSLGEWKTQM EETKAQDILG AVTLLLEGVM AARGQLGPTC LSSLLGQLSG QVRLLLGALQ SLLGTQLPPQ GRTTAHKDPN AIFLSFQHLL RGKVRFLMLV GGSTLCVRRA PPTTAVPSRT SLVLTLNELP NRTSGLLETN FTASARTTGS GLLKWQQGFR AKIPGLLNQT SRSLDQIPGY LNRIHELLNG TRGLFPGPSR RTLGAPDISS GTSDTGSLPP NLQPGYSPSP THPPTGQYTL FPLPPTLPTP VVQLHPLLPD PSAPTPTPTS PLLNTSYTHS QNLSQEGHHH HHH
Product Science Overview
Thrombopoietin (TPO) is a crucial glycoprotein hormone primarily responsible for the regulation of platelet production in the body. It plays a significant role in hematopoiesis, particularly in the development of megakaryocytes, the bone marrow cells that produce platelets. Recombinant human thrombopoietin (rhTPO) is a synthetic form of this hormone, engineered to mimic the natural TPO and used in various clinical applications.
The journey of TPO began with its purification in 1994. This milestone led to the development of two recombinant forms of the c-Mpl ligand: recombinant human thrombopoietin (rhTPO) and pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) . These recombinant forms have undergone extensive clinical investigations to evaluate their efficacy and safety.
Recombinant human thrombopoietin has shown promise in several clinical settings:
-
Thrombocytopenia Management: Thrombocytopenia, a condition characterized by low platelet counts, is a common issue in patients undergoing chemotherapy, stem cell transplantation, and those with chronic liver disease or immune thrombocytopenia (ITP). RhTPO has been effective in reducing thrombocytopenia in these patients .
-
Pregnancy: RhTPO has emerged as a novel therapeutic option for managing immune thrombocytopenia in pregnant women. Clinical studies have reported successful outcomes in increasing platelet counts and reducing bleeding risks in such patients .
-
Other Potential Uses: Animal studies suggest that TPO may be beneficial in reducing surgical thrombocytopenia and bleeding, expanding pluripotent stem cells ex vivo, and serving as a radioprotectant .
While rhTPO has demonstrated significant potential, its use is not without challenges. Clinical trials have shown that rhTPO is a potent stimulator of megakaryocyte growth and platelet production. However, its benefits in stem cell transplantation and leukemia chemotherapy remain inconclusive . Ongoing and future studies are essential to fully understand the clinical role of rhTPO and its long-term safety.
